Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality.
Fiche publication
Date publication
septembre 2022
Journal
Frontiers in immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GOUMON Yannick
Tous les auteurs :
Schneider F, Le Borgne P, Herbrecht JE, Danion F, Solis M, Hellé S, Betscha C, Clere-Jehl R, Lefebvre F, Castelain V, Goumon Y, Metz-Boutigue MH
Lien Pubmed
Résumé
Neuroendocrine cells release Catestatin (CST) from Chromogranin A (CgA) to regulate stress responses. As regards COVID-19 patients (COVID+) requiring oxygen supply, to date nobody has studied CST as a potential mediator in the regulation of immunity.
Mots clés
COVID, Catestatin, Chromogranin A, Innate immunity, critically ill, hypoxia, nosocomial disease
Référence
Front Immunol. 2022 09 29;13:985472